vs
艾玛迪斯（GDS）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是艾玛迪斯的1.9倍（$772.1M vs $405.6M），Revvity净利率更高（12.7% vs -0.1%，领先12.8%），Revvity自由现金流更多（$161.8M vs $-96.3M）
西班牙跨国科技企业艾玛迪斯是全球领先的旅游技术服务商，面向航空、酒店、旅行社等各类旅游相关企业提供定制化软件解决方案，业务覆盖全球市场，助力旅游行业客户优化运营效率、提升服务体验。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
GDS vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.9倍
$405.6M
净利率更高
RVTY
高出12.8%
-0.1%
自由现金流更多
RVTY
多$258.1M
$-96.3M
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $405.6M | $772.1M |
| 净利润 | $-373.0K | $98.4M |
| 毛利率 | 22.1% | — |
| 营业利润率 | — | 14.5% |
| 净利率 | -0.1% | 12.7% |
| 营收同比 | — | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GDSRVTY
| Q4 25 | — | $772.1M | ||
| Q3 25 | $405.6M | $698.9M | ||
| Q2 25 | $404.9M | $720.3M | ||
| Q1 25 | $375.3M | $664.8M | ||
| Q4 24 | — | $729.4M | ||
| Q3 24 | $422.6M | $684.0M | ||
| Q2 24 | $388.9M | $691.7M | ||
| Q1 24 | $363.9M | $649.9M |
净利润GDSRVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | $-373.0K | $46.7M | ||
| Q2 25 | $-240.0K | $53.9M | ||
| Q1 25 | $-145.0K | $42.2M | ||
| Q4 24 | — | $94.6M | ||
| Q3 24 | $-32.9M | $94.4M | ||
| Q2 24 | $-31.9M | $55.4M | ||
| Q1 24 | $-47.8M | $26.0M |
毛利率GDSRVTY
| Q4 25 | — | — | ||
| Q3 25 | 22.1% | 53.6% | ||
| Q2 25 | 23.8% | 54.5% | ||
| Q1 25 | 23.7% | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 22.2% | 56.3% | ||
| Q2 24 | 22.6% | 55.7% | ||
| Q1 24 | 21.8% | 54.6% |
营业利润率GDSRVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 12.6% | ||
| Q1 25 | — | 10.9% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | 10.8% | 14.3% | ||
| Q2 24 | 11.2% | 12.4% | ||
| Q1 24 | 8.3% | 6.8% |
净利率GDSRVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | -0.1% | 6.7% | ||
| Q2 25 | -0.1% | 7.5% | ||
| Q1 25 | -0.0% | 6.4% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | -7.8% | 13.8% | ||
| Q2 24 | -8.2% | 8.0% | ||
| Q1 24 | -13.1% | 4.0% |
每股收益（稀释后）GDSRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.6B | $7.3B |
| 总资产 | $11.0B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GDSRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
股东权益GDSRVTY
| Q4 25 | — | $7.3B | ||
| Q3 25 | $3.6B | $7.4B | ||
| Q2 25 | $3.4B | $7.6B | ||
| Q1 25 | $3.2B | $7.6B | ||
| Q4 24 | — | $7.7B | ||
| Q3 24 | $2.7B | $7.9B | ||
| Q2 24 | $2.6B | $7.9B | ||
| Q1 24 | $2.6B | $7.8B |
总资产GDSRVTY
| Q4 25 | — | $12.2B | ||
| Q3 25 | $11.0B | $12.1B | ||
| Q2 25 | $11.1B | $12.4B | ||
| Q1 25 | $10.1B | $12.4B | ||
| Q4 24 | — | $12.4B | ||
| Q3 24 | $11.7B | $12.8B | ||
| Q2 24 | $10.9B | $13.4B | ||
| Q1 24 | $10.5B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $103.5M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-96.3M | $161.8M |
| 自由现金流率自由现金流/营收 | -23.7% | 21.0% |
| 资本支出强度资本支出/营收 | 49.2% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流GDSRVTY
| Q4 25 | — | $182.0M | ||
| Q3 25 | $103.5M | $138.5M | ||
| Q2 25 | $120.8M | $134.3M | ||
| Q1 25 | — | $128.2M | ||
| Q4 24 | — | $174.2M | ||
| Q3 24 | $91.4M | $147.9M | ||
| Q2 24 | — | $158.6M | ||
| Q1 24 | — | $147.6M |
自由现金流GDSRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | $-96.3M | $120.0M | ||
| Q2 25 | $-55.8M | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | $-321.7M | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率GDSRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | -23.7% | 17.2% | ||
| Q2 25 | -13.8% | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | -76.1% | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度GDSRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | 49.2% | 2.6% | ||
| Q2 25 | 43.6% | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | 97.7% | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率GDSRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GDS
| Service revenue | $405.5M | 100% |
| Equipment sales | $2.8M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
